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Abstract
Purpose—To compare two laser photocoagulation techniques for treatment of diabetic macular
edema (DME): modified-ETDRS direct/grid photocoagulation (mETDRS) and a, potentially milder,
but potentially more extensive, mild macular grid (MMG) laser technique in which small mild burns
are placed throughout the macula, whether or not edema is present, and microaneurysms are not
treated directly.
Methods—263 subjects (mean age 59 years) with previously untreated DME were randomly
assigned to receive laser photocoagulation by mETDRS (N=162 eyes) or MMG (N=161 eyes)
technique. Visual acuity, fundus photographs and OCT measurements were obtained at baseline and
after 3.5, 8, and 12 months. Treatment was repeated if DME persisted.
Main Outcome Measure—Change in OCT measures at 12-months follow up.
Results—From baseline to 12 months, among eyes with baseline central subfield thickness ≥ 250
microns, central subfield thickening decreased by an average of 88 microns in the mETDRS group
and decreased by 49 microns in the MMG group (adjusted mean difference: 33 microns, 95%
confidence interval 5 to 61 microns, P=0.02). Weighted inner zone thickening by OCT decreased by
42 and 28 microns, respectively (adjusted mean difference: 14 microns, 95% confidence interval 1
to 27 microns, P=0.04), maximum retinal thickening (maximum of the central and four inner
subfields) decreased by 66 and 39 microns, respectively (adjusted mean difference: 27 microns, 95%
confidence interval 6 to 47 microns, P=0.01), and retinal volume decreased by 0.8 and 0.4 mm3,
respectively (adjusted mean difference: 0.3 mm3, 95% confidence interval 0.02 to 0.53 mm3,
P=0.03). At 12 months, the mean change in visual acuity was 0 letters in the mETDRS group and 2
letters worse in the MMG group (adjusted mean difference: 2 letters, 95% confidence interval −0.5
to 5 letters, P=0.10).
Conclusions—At 12 months after treatment, the MMG technique is less effective at reducing OCT
measured retinal thickening than the more extensively evaluated current mETDRS laser
photocoagulation approach. However, the visual acuity outcome with both approaches is not
substantially different. Given these findings a larger long-term trial of the MMG technique is not
justified.
Application to Clinical Practice—Modified ETDRS focal photocoagulation should continue as
a standard approach for treating diabetic macular edema.
Corresponding author: Donald S. Fong, M.D., c/o Jaeb Center for Health Research, 15310 Amberly Drive, Suite 350, Tampa, FL 33647;
Phone: (813) 975-8690, Fax: (800) 816-7601, E-mail: drcrnet@jaeb.org.
*The writing committee and a list of the members of the Diabetic Retinopathy Clinical Research Network (DRCR.net) participating in
the trial appear in the acknowledgements.
NIH Public Access
Author Manuscript
Arch Ophthalmol. Author manuscript; available in PMC 2008 September 15.
Published in final edited form as:














The Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated that focal (direct/
grid) laser photocoagulation reduces moderate vision loss from diabetic macular edema (DME)
by 50% or more. The effectiveness of focal laser treatment may be due in part to closure of
leaky microaneurysms, but the specific mechanisms by which focal photocoagulation reduces
DME is not known. Histopathological studies show changes located in the retina and retinal
pigment epithelium (RPE).1, 2 Some investigators have hypothesized that with reduced retinal
tissue following photocoagulation, autoregulation results in decreased retinal blood flow with
lower fluid flow resulting in decreased edema.3, 4 Others have suggested that the reduced
retinal blood flow is due to improved oxygenation following photocoagulation.4 Biochemical
and physiological studies suggest that resolution of the edema may also result from changes
in the biochemical processes within the retinal pigment epithelium (RPE).5–11 The
effectiveness of grid treatment alone (without focal treatment of microaneurysms) supports an
indirect effect of retinal photocoagulation on macular edema.11–14
Although effective, ETDRS protocol photocoagulation may require placement of burns close
to the center of the macula. Over time, laser burns may develop into areas of progressive RPE
and retinal atrophy that become larger than the original laser spot size and encroach upon
fixation. Photocoagulation for DME may be associated with loss of central vision, central
scotomas, and decreased color vision.15–16 In an attempt to reduce these adverse effects, many
retinal specialists now treat using burns that are lighter and less intense than originally specified
in the ETDRS (modified-ETDRS technique, mETDRS).16–19
An alternative approach (mild macular grid, MMG) is the application of mild, widely spaced
burns throughout the macula, avoiding the foveal region. By design, some burns could be
placed in clinically normal retina if the entire retina was not abnormally thickened, including
areas within the macula that are relatively distant from the area of thickening. The lighter burns
applied to the macula are theoretically less likely to result in thermal injury to the overlying
retina and less likely to break Bruch’s membrane. The widespread application also might lead
to improved oxygenation, development of healthier RPE, and overall physiologic improvement
of the entire macula. This improvement might lead to both resolution of edema and prevention
of edema recurrence. Burns placed in unthickened retina might help normalize the numerous
cellular changes in the retina induced by diabetes by the time DME develops. Effects on retinal
areas distant from the laser burn, as proposed for MMG, have been demonstrated in
photocoagulation used for proliferative retinopathy where regression of neovascularization
occurs distant from the laser burns.
The current study, comparing the MMG technique with the mETDRS technique in eyes with
previously untreated DME, was performed to determine whether the MMG technique might
provide enough added benefit over the mETDRS approach to warrant conducting a larger,
longer-term trial. This study was the first initiated by the Diabetic Retinopathy Clinical
Research Network (DRCR.net), which is funded by the National Eye Institute of the National
Institutes of Health, U.S. Department of Health and Human Services to support a multi-center
clinical trial research network dedicated to investigating diabetic retinopathy. Thus, an
additional purpose of the study was to certify the network sites and standardize procedures to
be used in subsequent studies.
Methods
The protocol and HIPAA-compliant informed consent forms were approved by multiple
institutional review boards. Each subject gave written informed consent to participate in the
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study. Study oversight was provided by an independent data and safety monitoring committee.
The study is listed on www.clinicaltrials.gov, under identifier NCT00071773.
Study Population
To be eligible for the study, a participant had to be at least 18 years old with type 1 or type 2
diabetes, have no history of renal failure requiring dialysis or renal transplant, and have one or
both eyes meeting the following criteria: (1) best corrected electronic-ETDRS visual acuity
letter score ≥ 19 (approximately 20/400 or better)20, (2) definite retinal thickening due to
previously untreated DME (and not primarily due to vitreoretinal interface disease as
determined by investigator clinical exam) within 500 microns of the macular center on clinical
examination, (3) retinal thickness measured on Optical Coherence Tomography (OCT) ≥ 250
microns in the central subfield or ≥ 300 microns in at least one of the four inner subfields, and
(4) no prior laser or other treatment for DME. Eyes were not eligible that had retinal thickening
from epiretinal membranes or vitreomacular traction (as determined by the investigator),
needed or had received panretinal scatter photocoagulation within the prior 4 months, YAG
capsulotomy within the prior 2 months, or major ocular surgery including cataract extraction
within the prior 6 months. A subject could have two study eyes in the trial only if both were
eligible at the time of study entry.
Synopsis of Study Design
After informed consent was obtained and eligibility confirmed, the randomly-assigned laser
treatment for each study eye (MMG or mETDRS) was obtained from the DRCR.net website.
For participants with one study eye, randomization was stratified according to the presence/
absence of unthickened subfields on OCT (to assure balance between treatment groups), with
the randomization of eyes having at least one unthickened subfield also stratified by clinical
center. For participants with two study eyes, one eye was randomly assigned to receive one
treatment technique and the other eye received the other treatment technique. Visual acuity
testers were masked to treatment assignment. Investigators by the nature of the study were not
masked.
After the initial laser treatment, follow-up visits were performed at 3.5 months (± 2 weeks), 8
months (± 4 weeks), and 12 months (± 4 weeks). Testing at each visit included measurement
of best corrected electronic-ETDRS20 acuity and OCT-measured retinal thickness by certified
evaluators. Macular laser photocoagulation was repeated if DME persisted and such treatment
was warranted in the opinion of the investigator according to the guidelines presented below.
The primary study outcome was change in OCT measures at 12-months follow up. Change in
visual acuity was evaluated as a secondary outcome.
Treatment Protocols
The two treatment techniques are detailed in Table 1. They differ in the intensity, density and
location of the laser burns. MMG burns are lighter and more diffuse in nature and are distributed
throughout the macula in both areas of thickened and unthickened retina. Microaneurysms are
not directly photocoagulated. In contrast, mETDRS direct/grid photocoagulation is comprised
of treating only areas of thickened retina (and areas of retinal nonperfusion) and leaking
microaneurysms. Although microaneurysms are directly treated, the treatment has been
modified from the original ETDRS protocol to not require a treatment-induced change in
microaneurysm color. The other primary modification to the original ETDRS protocol is that
the laser burns are less intense (gray) and smaller (50 microns). These changes were instituted
to reflect the approach currently in use in the US by most treating ophthalmologists, based on
a survey of DRCR.net investigators. The treatment sessions for both techniques generally were
completed in a single sitting.
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At each follow-up study visit, the investigator assessed whether persistent, recurrent or new
DME was present that warranted additional photocoagulation. In general, retreatment was to
be administered unless the DME had resolved or there was substantial improvement in the
DME in the opinion of the investigator (e.g., > 50% decrease in total macular thickened area
or > 50% decrease in retinal thickening by OCT in central or inner subfields with previous
retinal thickening). For the modified-ETDRS group, retreatment consisted of the same
modified-ETDRS treatment technique. For the MMG group, the first retreatment used the same
MMG technique limited to only the area of retinal thickening. If required, a second retreatment
used the modified-ETDRS technique (which allows focal treatment of leaking microaneurysms
in the area of retinal thickening).
Examination Procedures
At baseline and at each follow-up visit, visual acuity was measured by a certified evaluator
using the electronic-ETDRS procedure20 following a standardized refraction. OCT and
ETDRS-protocol fundus photographs (7-fields at baseline and 12 months, and 3-field at 3.5
and 8 months) were obtained by certified personnel. Adverse events related to treatment were
recorded on electronic case report forms completed at each study visit. OCTs, fundus
photographs, and fluorescein angiograms were sent to the Fundus Photograph Reading Center
at the University of Wisconsin-Madison for masked grading.
OCT images were obtained on each eye following pupil dilation by a certified operator using
the OCT3 throughout the study in 246 subjects. Scans were 6 mm in length and included the
6 radial line pattern (fast macular scan option with OCT3) for quantitative measures and the
cross hair pattern (6–12 to 9–3 o’clock) for qualitative assessment of retinal morphology. For
17 study participants, the OCT2 was initially utilized, but scans were eventually obtained using
the OCT3 during the course of the study for 14 of these subjects (OCT2 was used throughout
the study for 3 subjects). Scans were sent to the Reading Center where they were visually
inspected. For 19% of the 323 baseline scans and 13% of the 872 follow-up scans, the
automated thickness measurements were judged to be inaccurate and center point thickness
was manually determined and used to impute a value for the central subfield using a regression
equation (since the correlation of the two measures is 0.99).
Four principal quantitative OCT outcomes were examined: retinal thickness in the central
subfield, weighted inner zone thickness, maximum retinal thickening within the inner zone,
and retinal volume. Inner zone thickness was averaged across the central subfield and the four
inner subfields according to retinal area to calculate a weighted inner zone thickness; the larger
inner subfields were each given a weight of 8/9 disc areas and the smaller central subfield was
given a weight of 4/9 disc areas. Retinal thickening was defined as the observed thickness
minus the mean normal thickness in each subfield (normative data based on unpublished data
provided by Carl Zeiss Meditec from a study of 260 nondiabetic eyes with a normal macula in
which the following mean thicknesses were determined: central subfield = 202 ± 22 microns,
inner temporal = 267 ± 17 microns, inner superior = 269 ± 16 microns, inner nasal = 267 ± 17
microns, and inner inferior = 271 ± 16 microns). Maximum retinal thickening was the largest
value of thickening among the central and each of the 4 inner subfields. Retinal volume was
the automated value taken directly from the OCT scan, representing a weighted average of the
central, inner and outer subfields multiplied by the area of the grid, expressed in mm3. Retinal
morphology was assessed from OCT images for cystoid abnormalities (five-level grading
scale), central subretinal fluid (three-level grading scale) and vitreoretinal interface
abnormalities (three-level grading scale).
The grading method for color fundus photographs was the same as the method used in the
ETDRS,21 except that areas of retinal thickening and hard exudates (in color photographs)
were estimated as continuous variables (in disc area units, DA) rather than on ordinal scales.
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In order to assess change in area of retinal thickening, change in the square root of the area,
which represents the average diameter of the area in disc diameters (DD), was used. A change
of ≥ 0.6 DD was considered substantial, e.g., from 6 DA (2.4 DD) to 3.4 DA (1.8 DD) or from
2 DA (1.4 DD) to 0.6 DA (0.8 DD). Due to the difficulty in assessing very small areas of
thickening, and to avoid placing undue weight on disappearance of small areas, the square root
of any area < 0.17 DA (including 0) was set to 0.4 DD.
Statistical Methods
The primary outcome was change in retinal thickening in the central subfield on OCT. Change
in visual acuity was a secondary outcome. The study was designed to have a minimum sample
size of 200 subjects with 50 sites each enrolling 4 subjects. With a sample size of 200 eyes and
assuming no more than 10% loss to follow up and a 2-sided alpha of 0.05, the study was
designed to have 90% power to detect a minimum difference between groups of 50 microns
in the reduction of central retinal thickening, assuming that the common standard deviation for
the change from baseline was 100 microns. With the actual sample size of 213 eyes that had
baseline central subfield thickness ≥ 250 microns and 12-month follow up, and using the
observed common standard deviation of 96 microns as a better approximation of the population
value than the 100 microns used in the prestudy power calculation, statistical power was 90%
to detect a difference in change in OCT central subfield thickening between groups of 43
microns and 80% to detect a difference of 37 microns. For the visual acuity analysis that
included 284 eyes with baseline and 12-month data, power was 90% to detect a difference in
visual acuity between groups of 4.3 letters and 80% to detect a difference of 3.7 letters.
Continuous OCT and visual acuity outcome measures were assessed using repeated measures
least squares regression models adjusted for baseline values and accounting for the correlated
data from subjects with two study eyes. Adjusted mean differences and confidence intervals
were determined from these models. Similarly, repeated measures generalized estimating
equations (GEE) models adjusting for baseline values were used for binary outcomes. When
outliers were truncated at ± 3 standard deviations from the mean, there was little effect on the
results (data not shown). Analyses using the last observation carried forward (LOCF)
imputation method gave similar results (data not shown). Eyes were deemed to be within the
normal range if central and inner subfield values were all within 2 standard deviations of the
mean values obtained from normal eyes. Analyses were also conducted on the subset of subjects
with two symmetrically-involved study eyes, defined as having an inter-eye difference of less
than 100 microns in central retinal thickening and less than 15 letters in visual acuity.
Results
Between July 2003 and October 2004, 263 subjects (mean age 59±11 years; 40% women) were
enrolled at 79 sites in 30 states. There were 323 study eyes with DME that were randomly
assigned to either mETDRS treatment (N=162) or to MMG treatment (N=161). Mean visual
acuity in study eyes was 20/32 (74±13 letters) and mean OCT central subfield retinal thickness
was 340±123 microns. Nineteen percent of eyes had a central subfield thickness < 250 microns
but were eligible based on having at least one of the four inner subfields with thickness ≥ 300
microns. The baseline characteristics of the two groups were similar (Table 2).
Follow Up
Figure 1 outlines the 12-month follow up for all eyes, which was completed for 142 (88%) of
the 162 eyes in the mETDRS group and 143 (89%) of the 161 eyes in the MMG group. There
were 4 participants who died during the study, representing 3 study eyes in the mETDRS group
and 4 in the MMG group. Twenty-two participants were lost to follow up or withdrew,
representing 17 and 13 study eyes from the mETDRS and MMG groups, respectively. The
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mean change in HbA1c between baseline and 12 months was similar in each group (−0.1% in
the mETDRS group and −0.2% in the MMG group).
Laser and Other Treatments Received for DME
All eyes received the randomization-assigned treatment regimen at baseline, except for two
eyes of two subjects both of whom had two study eyes and did not return for treatment of the
second eye (neither subject had any follow up).
The proportion of eyes that were retreated during the 12 months of follow up was similar in
the two groups (P=0.35): in the mETDRS and MMG groups, respectively, 59 (42%) and 47
(33%) had no additional laser treatment, 47 (33%) and 58 (41%) were retreated once, and 36
(25%) and 38 (27%) were retreated twice.
Prior to the 12-month visit, DME therapy other than laser was received in 2 eyes assigned to
mETDRS (vitrectomy in one and peribulbar triamcinolone acetonide in the other).
Effect of Treatment on Retinal Thickening
Central subfield thickening, weighted inner zone thickening, maximum retinal thickening and
retinal volume all decreased over the 12-month period in both treatment groups (P<0.002 for
each measure in both groups comparing baseline and 12 months). The reduction in retinal
thickening was slightly more evident in the mETDRS group than in the MMG group (Table
3). There also was a trend for resolution of DME by each of these measures that was slightly
more frequent in the mETDRS group (Figure 2). From baseline to 12 months, among eyes with
baseline central subfield thickness ≥ 250 microns, central subfield thickening decreased by an
average of 88 microns in the mETDRS group and decreased by 49 microns in the MMG group
(adjusted mean difference: 33 microns, 95% confidence interval 5 to 61 microns, P=0.02).
Weighted inner zone thickening decreased by 42 and 28 microns respectively (adjusted mean
difference: 14 microns, 95% confidence interval 1 to 27 microns, P=0.04), maximum retinal
thickening decreased by an average of 66 microns in the mETDRS group and 39 microns in
the MMG group (adjusted mean difference: 27 microns, 95% confidence interval 6 to 47
microns, P=0.01), and retinal volume decreased by 0.8 and 0.4 mm3, respectively (adjusted
mean difference: 0.3 mm3, 95% confidence interval 0.02 to 0.53 mm3, P=0.03). Among eyes
with central and all four inner subfield thickness measurements at 12 months, the central
subfield and all four inner subfields were all within the normal range in 29 (23%) of eyes in
the mETDRS group and 21 (17%) in the MMG group (P=0.67). The treatment group
differences were larger with greater retinal thickening at baseline (Table 4).
On fundus photographs, at 12 months, the average diameter of the area of DME had decreased
by 0.2 DD in the mETDRS group and by 0.08 DD in the MMG group (P=0.07). DME had
decreased by = 0.6 DD in 41 (31%) and 28 (22%) of eyes in the mETDRS and MMG groups,
respectively (P=0.03), and had increased by this amount in 22 (17%) and 26 (20%), respectively
(P=0.26).
Effect of Treatment on Visual Acuity
At 12 months, the mean change in visual acuity was 0 letters in the mETDRS group and 2
letters worse in the MMG group (adjusted mean difference: 2 letters, 95% confidence interval
−0.5 to 5 letters, P=0.10, Table 5). Ten (7%) and 7 (5%) of eyes were improved by 15 or more
letters from baseline in the two groups, respectively (P=0.24), and 10 (7%) and 14 (10%) were
worse by 15 or more letters (P=0.37).
Page 6













Results for Subjects with Two Study Eyes
In an analysis of the 34 subjects with two study eyes and relatively symmetrical DME at
baseline, defined as having an inter-eye difference of less than 100 microns in central retinal
thickening and less than 15 letters in visual acuity, there were no significant differences
between mETDRS and MMG groups in the mean change in central retinal thickening (P=0.91)
or in the change in visual acuity (P=0.13) from baseline to 12 months.
Adverse Effects
The only major treatment-related adverse event reported was a neurosensory detachment
following the initial laser treatment in the MMG group, which resolved after 1 month. In this
case, baseline visual acuity was 20/25 (80 letters) and 12-month acuity was 20/50 (67 letters).
Review of the post-treatment photographs did not suggest that the photocoagulation treatment
was heavier than the photographic standard for this treatment.
Discussion
At present, despite the enthusiasm for evaluation of several novel treatments for DME including
intravitreal therapies for DME (e.g., corticosteroids, and anti-VEGF drugs), laser
photocoagulation remains the current standard of care and the only treatment with proven
efficacy in a large-scale clinical trial for this condition. This DRCRnet trial was designed to
compare two laser techniques for previously untreated DME. One technique was the most
commonly used approach in current clinical practice among DRCRnet investigators, a
modification of the original technique used in the ETDRS (mETDRS). The other approach has
theoretical advantages in which laser is given in a grid without specifically treating
microaneurysms (MMG). After 12 months of follow up, there was no indication that the eyes
treated with MMG had a better outcome than those receiving mETDRS treatment, and in fact
eyes in the mETDRS group experienced a slightly greater reduction in retinal thickening and
a trend towards a slightly better visual acuity outcome. Although a decrease in retinal
thickening was observed with both treatments, this trial did not include an untreated control
group, thus preventing determination of how the observed changes in retinal thickening would
have differed from the natural history of untreated DME. Unexpected adverse effects of
treatment were minimal.
The primary outcome measure of the study was change in retinal thickening as a surrogate for
longer-term change in visual acuity. In phase 2 studies, surrogate outcome measures are often
used to determine whether there is sufficient evidence of treatment effect to proceed to a longer-
term, more costly phase 3 study with visual acuity as the primary outcome. The trial had a
sample size that was sufficiently large so that it is unlikely that a true benefit of MMG over
the mETDRS approach in reducing retinal thickening after 12 months went undetected.
Furthermore, since the results slightly favored the mETDRS approach, it is even more unlikely
that a true meaningful beneficial effect on retinal thickening of MMG over the mETDRS
treatment after 12 months was missed. While the correlation between retinal thickening and
visual acuity is only moderate,23 the study had greater than 90% statistical power to detect at
least a one line difference in mean acuity between groups. Thus, it is unlikely that a meaningful
beneficial effect of MMG treatment on visual acuity after 12-months was missed. The treatment
groups were generally well balanced with regard to baseline factors. Retinal thickening was
slightly greater in the MMG group but this was controlled for in the analyses and did not
confound the results. Bias is unlikely to have prevented detection of a true benefit of MMG,
because both OCT and fundus photographs were used to document macular edema and both
measures were graded at a reading center masked to treatment group. Visual acuity was
measured using a computerized system that reduces technician bias. The large number of
investigators could have increased the variation in treatment technique compared with a smaller
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number of surgeons but this is not a likely explanation for the lack of difference between groups.
It also seems unlikely that a relative benefit of MMG compared with mETDRS would have
been seen with longer follow up since there was no suggestion of benefit after 12 months.
In conclusion, despite potential theoretical advantages, after 12 months of follow up the MMG
laser technique is less effective in reducing OCT measure retinal thickening than the mETDRS
technique frequently used in current clinical practice. However, the visual acuity outcomes
with both approaches are not substantially different. Thus, this study does not provide data to
suggest that a larger long-term trial of the MMG technique is likely to show substantial clinical
benefit over the current mETDRS approach.
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Morgan Harper (V); Lydia Polanco (V); Linda McCall (P); Louisville, CO - Eldorado Retina Associates, P.C.
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Madison, WI - University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service (4): Justin Gottlieb (I);
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Minneapolis, MN - University of Minnesota (4): Timothy W. Olsen (I); Sally Cook (C); Ann M. Holleschau (C);
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M. Ceresa (V); Connie J. Dwiggins (V); Russ Burris (P); William R. Richmond (P); Paducah, KY - Paducah Retinal
Center (4): Carl W. Baker (I); Tracey M. Caldwell (C); Lynnette F. Lambert (V); Dawn D. Smith (P); Peabody, MA
- Lahey Clinic, Inc./The Eye Institute (4): Jeffrey L. Marx (I); Fleming D. Wertz (I); Avon P. Stewart (C); Steve
M. Kelly (C); Patti-Ann L. Morse (C); Michael R. Johnson (V); Tracy Scrivano (V); Ellen L. Casazza (P); Richard
Selter (P); Philadelphia, PA - University of Pennsylvania Scheie Eye Institute (4): Alexander J. Brucker (I); Robert
A. Stoltz (I); Joan C. DuPont (C); Sheri Drossner (C); Tanya Metelitsina (V); Tomas S. Aleman (P); Cheryl Devine
(P); William Nyberg (P); Laurel Weeney (P); Elizabeth A. Windsor (P); Portland, OR - Casey Eye Institute (4):
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Ortiz (I); Madelyn Alvarez (C); Rita L. Johnson (C); Sandra E. Montoya (C); Ross Jarrett (P); Tampa, FL - University
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(V); Wyatt Saxon (P); Winston-Salem, NC - Wake Forest University Eye Center (4): Craig Michael Greven (I);
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Feehan (V); Brenda K. Kilbourne (V); Angela D. Listerman (V); Donald E. Kuitula (P); Sue Weatherbee (P);
Greenbelt, MD - The Retina Group of Washington (3): William B. Phillips, II (I); Richard Garfinkel (I); Manfred
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Jeffrey M. Napoli (P); Irvine, CA - University of California, Irvine (2): Baruch D. Kuppermann (I); Jeff Grijalva
(C); Rosie Magallon (V); Bret Trump (P); Lexington, KY - University of Kentucky (2): Andrew Pearson (I); Michele
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Linda, CA -Loma Linda University Health Care, Department of Ophthalmology (2): Joseph T. Fan (I); Michael
E. Rauser (I); Arun K. Chakrabarty (C); William H. Kiernan (V); Gene Saldana (P); Los Angeles, CA - Jules Stein
Eye Institute (2): Steven D. Schwartz (I); Christine R. Gonzales (I); Anurag Gupta (I); Rosaleen Ostrick (C); Melissa
Chun (V); Jennie Kageyama (V); Bita Shokouh (V); David L. Le Beck (P); Mirella Tetreault (P); Joel Moral (P);
Milwaukee, WI - Medical College of Wisconsin (2): Judy E. Kim (I); Dennis P. Han (I); Troy S. Drescher (C);
Christine Y. Lange (C); Kelly Reiter (C); Vicki Barwick (V); Joseph R. Beringer (P); Richmond, VA - Richmond
Retinal Associates/Virginia Eye Institute (2): George Sanborn (I); Byron S. Ladd (I); Melissa Vaughan (C); Robin
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- California Retina Consultants (2): Dante J. Pieramici (I); Tamara A. Norton (C); Elizabeth A. Robbins (C); Kelly
Avery (V); Liz Tramel (V); Karen Boyer (P); Matthew Giust (P); Melissa Kruzel (P); St. Louis, MO -Barnes Retina
Institute (2): Rajendra S. Apte (I); Ginny S. Nobel (C); Lynda K. Boyd (V); Carolyn L. Walters (V); Matt L. Raeber
(P); Jarrod Wehmeier (P); Towson, MD -Retina Specialists (2): Raymond N. Sjaarda (I); John T. Thompson (I);
Maryanth Constantine (C); Janette L. Herron (V); Marcia A. Sentz (V); Leslie G. Russel (P); John L. Davis (V);
Ventura, CA - Miramar Eye Specialist Medical Group (2): Joel M. Corwin (I); Donald A. Frambach (I); Lisa Jue
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(Director), Larry Hubbard (Associate Director), James Reimers (Lead Color Photography Evaluator), Pamela Vargo
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Flow chart showing visit completion and reasons for study discontinuation in the two treatment
groups.
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Resolution of edema in the two treatment groups at 3.5, 8, and 12 months for OCT
measurements: A. Central subfield thickening: only includes eyes with at least 275 microns of
thickness at baseline; resolution defined as central subfield < 250 microns and at least a 50
micron decrease. B. Weighted inner zone thickness: only includes eyes with at least 300
microns of thickness at baseline; resolution defined as < 285 microns and at least a 50 micron
decrease. C. Maximum retinal thickening in the central subfield, or any inner subfield: only
includes eyes with at least 75 microns of thickening at baseline; resolution defined as < 50
microns of thickening and at least a 50 micron decrease from baseline. D. Retinal volume: only
includes eyes with volume at least 7.82 mm3 (3 standard deviations greater than normal) at
baseline; resolution defined as thickening within 2 standard deviations of normal in each
subfield and volume decreased at least 0.5 mm3.
N refers to the number of eyes with edema on the measure at baseline and with a gradable OCT
at the visit. Dark bars are mETDRS group and lighter bars are MMG group.
P-values obtained using repeated measures least squares regression models adjusting for
baseline values and accounting for the correlated data from subjects with two study eyes.
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Modified-ETDRS (mETDRS) and the Mild Macular Grid (MMG) Laser Photocoagulation Techniques
Burn Characteristic Direct/Grid Photocoagulation (Modified-ETDRS
technique)
Mild Macular Grid Photocoagulation
Technique
Direct Treatment Directly treat all leaking microaneurysms in areas of
retinal thickening between 500 and3000 microns from
the center of the macula (but not within 500 microns of
disc)
Not applicable
Change in MA Color with Direct
Treatment
Not required, but at least a mild gray-white burn should
be evident beneath all microaneurysms
Not applicable
Burn Size for Direct Treatment 50 microns Not applicable
Burn Duration for Direct
Treatment
0.05 to 0.1 sec Not applicable
Grid Treatment Applied to all areas with diffuse leakage or
nonperfusion within area described below for treatment
Applied to entire area described below for
treatment (including unthickened retina)
Area Considered for Grid
Treatment
500 to 3000 microns superiorly, nasally and inferiorly
from center of macula 500 to 3500 microns temporally
from macular center
No burns are placed within 500 microns of disc
500 to 3000 microns superiorly, nasally and
inferiorly from center of macula
500 to 3500 microns temporally from
macular center
No burns are placed within 500 microns of
the disc
Burn Size for Grid Treatment 50 microns 50 microns
Burn Duration for Grid Treatment 0.05 to 0.1 sec 0.05 to 0.1 sec
Burn Intensity for Grid Treatment Barely visible (light gray) Barely visible (light gray)
Burn Separation for Grid
Treatment
2 visible burn widths apart 200 to 300 total burns evenly distributed over
the treatment area outlined above (approx. 2
to 3 burn widths apart)
Wavelength (Grid and Focal
Treatment)
Green to yellow wavelengths Green to yellow wavelengths



















MMG Group (N=161 eyes)
*
Subject Characteristics
Gender: Women - N(%) 61(38%) 69(43%)




 Hispanic or Latino 17(10%) 13(8%)
 Asian 8(5%) 7(4%)
 Other 6(4%) 7(4%)
Diabetes Type - N(%)
 Type 1 12(7%) 9(6%)
 Type 2 150(93%) 152(94%)
Duration of Diabetes (years) - Mean±SD 14±9 13±8
HbA1c (%) - Mean±SD 8.2±1.9 8.2±2.1
Ocular Characteristics
E-ETDRS20 Visual Acuity (letter score) - N(%)
 ≥ 84: 20/20 or better 43(27%) 32(20%)
 83–69: 20/25 to 20/40 76(47%) 91(57%)
 68–49: 20/50 to 20/100 36(22%) 27(17%)
 48–34: 20/125 to 20/200 7(4%) 7(4%)
 33–19: 20/250–20/400 0(0%) 4(2%)
  Mean±SD – letters 74±12 73±14
OCT
 Central Subfield Thickness (microns) Mean±SD 335±128 346±118
 Maximum retinal thickening of central and inner subfields (microns, see
text) Mean±SD
148±122 163±111
 Number of eyes with at least 1 unthickened subfield† - N(%) 97(60%) 89(55%)
Fundus Photography
Retinopathy Severity21‡ - N(%)
 Mild NPDR (level 35) 25(15%) 17(11%)
 Moderate NPDR (level 43) 21(13%) 22(14%)
 Moderately severe NPDR (level 47) 79(49%) 76(47%)
 Severe NPDR (level 53) 16(10%) 29(18%)
 Mild PDR (level 61) 10(6%) 9(6%)
 Moderate PDR (level 65) 5(3%) 1(1%)
 High Risk PDR (levels 71 and 75) 0(0%) 0(0%)
Clinically Significant Macular Edema23‡ - N(%)
 None 12(7%) 10(6%)
 Questionable 3(2%) 2(1%)
 Zone of retinal thickening ≥ 1 disc area, within 1 disc diameter from center. 6(4%) 3(2%)
 Retinal thickening or adjacent hard exudates ≤ 500μ from center but no
thickening in center
18(11%) 17(11%)
 Retinal thickening or adjacent hard exudates ≤ 500μ from center with
questionable thickening in center
19(12%) 17(11%)
 Retinal thickening or adjacent hard exudates ≤ 500μ from center with
definite thickening in center
99(61%) 109(68%)
Area of Hard Exudates (within the Grid)
 Mean ± SD - Disc Area 0.1 ± 0.2 0.1 ± 0.2
Area of Retinal Thickening (in the Inner Zone)
 Mean ± SD - Disc Area 1.7 ± 1.3 1.9 ± 1.3
Area of Retinal Thickening (within the Grid)
 Mean ± SD - Disc Area 4.1 ± 3.4 5.0 ± 3.7
*
Subjects with two study eyes are included in both groups
†
Based on clinician assessment of the OCT
‡
Nongradable for up to 3% of eyes per group
Missing data for OCT and photographic measurements of up to 6 eyes per group































































































































































































































































































































































































































































































































































































































































































































































Changes in Retinal Thickening from Baseline to 12 Months in the Two Treatment
Groups Stratified by Degree of Thickening at Baseline
mETDRS Group MMG Group
N mean ± SD N mean ± SD
Change in Central Subfield Thickening at 12 Months*
Total 106 −88 ± 138 107 −49 ± 122
Baseline Central Subfield Thickness*
 250–349 microns 62 −22 ± 62 53 −7 ± 79
 350–449 microns 22 −75 ± 84 32 −74 ± 100
 ≥ 450 microns 22 −285 ± 155 22 −112 ± 189
P-value for interaction† <0.001‡ / 0.04§
Change in Weighted Inner Zone Thickening at 12 Months
Total 123 −42 ± 83 127 −28 ± 67
Baseline Weighted Inner Zone Thickness
 250–349 microns 88 −14 ± 42 81 −12 ± 52
 350–449 microns 22 −55 ± 60 36 −49 ± 56
 ≥ 450 microns 13 −208 ± 120 9 −92 ± 146
P-value for interaction† <0.001‡ / 0.04§
Change in Maximum Retinal Thickening at 12 Months||
Total 139 −66 ± 123 134 −39 ± 114
Baseline Maximum Retinal Thickening
 0 – 99 microns 63 −4 ± 53 49 +17 ± 86
 100 – 199 microns 38 −51 ± 65 43 −55 ± 73
 ≥ 200 microns 38 −184 ± 162 42 −89 ± 147
P-value for interaction† <0.001‡ / 0.24§
Change in Retinal Volume at 12 Months
Total 107 −0.8 ± 1.4 91 −0.4 ± 1.3
Baseline Retinal Volume
 < 8 mm3 54 −0.2 ± 0.5 33 −0.4 ± 0.4
 8 – < 9 mm3 29 −0.6 ± 0.8 29 0.2 ± 1.5
 ≥ 9 mm3 24 −2.3 ± 2.1 29 −1.1 ± 1.4
P-value for interaction† 0.03‡ / 0.38§
*
Central subfield thickening includes only eyes with central subfield thickness = 250 microns at baseline
†
Statistical test for whether treatment group difference varies according to baseline OCT measurement. P-value obtained using repeated measures least
squares regression models adjusting for baseline values and accounting for the correlated data from subjects with 2 study eyes.
‡
P-value based on the absolute change from baseline to follow up
§
P-value based on the log of the ratio of follow up to baseline
||
Maximum of central and 4 inner subfields
Note one eye in the MMG group had baseline Weighted Inner Zone thickness < 250 microns
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